Begin main content

Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines

Last updated: April 13, 2017
Project Number: RB1083-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the comparative clinical effectiveness of sustained release oral morphine (SROM) versus standard of care (i.e., methadone or buprenorphine/naloxone) in opioid use disorder?
  2. What is the comparative clinical effectiveness of injectable hydromorphone or prescription diacetylmorphine versus standard of care (i.e., methadone or buprenorphine/naloxone) in opioid abuse disorder?
  3. What is the comparative clinical effectiveness of SROM versus injectable hydromorphone or prescription diacetylmorphine in opioid use disorder?
  4. What is the cost-effectiveness of SROM in opioid use disorder?
  5. What is the cost-effectiveness of injectable hydromorphone or prescription diacetylmorphine in opioid use disorder?
  6. What are the evidence-based guidelines regarding the use of SROM, injectable hydromorphone or prescription diacetylmorphine for opioid abuse treatment?

Key Message

Four systematic reviews, seven randomized controlled trials, two non-randomized studies and one economic evaluation were identified regarding sustained release oral morphine, injectable hydromorphone, or prescription diacetylmorphine for opioid use disorder. Additionally, one evidence-based guideline was identified regarding sustained release oral morphine, injectable hydromorphone, or prescription diacetylmorphine for opioid use disorder.